Last reviewed · How we verify
Prednisolone + valaciclovir
Prednisolone suppresses immune and inflammatory responses while valaciclovir inhibits viral DNA replication, together reducing inflammation and controlling herpes virus infection.
Prednisolone suppresses immune and inflammatory responses while valaciclovir inhibits viral DNA replication, together reducing inflammation and controlling herpes virus infection. Used for Herpes zoster (shingles) with inflammatory complications, Bell's palsy associated with herpes simplex virus.
At a glance
| Generic name | Prednisolone + valaciclovir |
|---|---|
| Sponsor | Uppsala University Hospital |
| Drug class | Corticosteroid + antiviral combination |
| Target | Glucocorticoid receptor (prednisolone); herpes simplex virus and varicella-zoster virus DNA polymerase (valaciclovir) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Prednisolone is a corticosteroid that decreases immune cell activity and inflammatory mediator production. Valaciclovir is a prodrug of acyclovir that inhibits herpes simplex virus and varicella-zoster virus DNA polymerase, preventing viral replication. The combination addresses both the inflammatory and infectious components of certain viral conditions.
Approved indications
- Herpes zoster (shingles) with inflammatory complications
- Bell's palsy associated with herpes simplex virus
Common side effects
- Nausea
- Headache
- Immunosuppression-related infections
- Hyperglycemia
- Insomnia
Key clinical trials
- Ultrasound-Guided Thoracic Paravertebral Block With Steroid and Local Anesthetic for Acute Herpes Zoster: Effects on Pain Control and Prevention of Postherpetic Neuralgia (PHASE3)
- A Study of the Safety, Tolerability and Prelinminary Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis (PHASE1)
- Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis (PHASE4)
- Scandinavian Bell's Palsy Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prednisolone + valaciclovir CI brief — competitive landscape report
- Prednisolone + valaciclovir updates RSS · CI watch RSS
- Uppsala University Hospital portfolio CI